Pfizer Cancer Therapy Shows Promise in Trial

Pfizer's combination therapy involving Talzenna and Xtandi has achieved a significant milestone, meeting its primary goal in a Phase 3 prostate cancer trial. The positive results from the TALAPRO-3 study are expected to bolster the drug's potential in treating advanced prostate cancer. This clinical success could lead to expanded treatment options for patients and represents a notable advancement for Pfizer's oncology portfolio, potentially driving future revenue growth.